Finance

Beta
Lists
SYK:NYSE
Stryker Corp
$305.23
-0.83%
(-2.57) 1D
Jun 22, 1:58:29 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SYK...
Open
$307.57
High
$311.82
Low
$303.51
Mkt. cap
117.01B
Avg. vol.
2.86M
Volume
952.75K
Dividend
1.15%
Quarterly dividend
$0.88
Ex-dividend date
Jun 30, 2026
P/E ratio
35.35
52-wk high
$404.87
52-wk low
$281.00
EPS
$8.63
Beta
0.78
Shares outstanding
383.36M
No. of employees
56K
Open
$307.57
High
$311.82
Low
$303.51
Mkt. cap
117.01B
Avg. vol.
2.86M
Volume
952.75K
Dividend
1.15%
Quarterly dividend
$0.88
Ex-dividend date
Jun 30, 2026
P/E ratio
35.35
52-wk high
$404.87
52-wk low
$281.00
EPS
$8.63
Beta
0.78
Shares outstanding
383.36M
No. of employees
56K
Analyst outlook
Analyst Ratings
Based on 21 analysts giving stock ratings to SYK in the past 3 months
Strong Buy
Buy
17
Hold
4
Sell
0
12 month forecast
Based on 21 Wall Street analysts offering 12 month price targets for SYK in the last 3 months.
Highest
Current $305.23
$455.00 (+49.07%)
Average
$388.25 (+27.20%)
Lowest
$315.00 (+3.20%)
News stories
From sources across the web
Profile
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States. The company is ranked 195th on the Fortune 500 and 331st on the Forbes Global 2000. Wikipedia
About Stryker Corp
CEOKevin A. Lobo
Employees56K
Founded1941
HeadquartersKalamazoo, Michigan, United States
SectorMedical device
Websitestryker.com
Analyst Ratings
Based on 21 analysts giving stock ratings to SYK in the past 3 months
Strong Buy
Buy
17
Hold
4
Sell
0
12 month forecast
Based on 21 Wall Street analysts offering 12 month price targets for SYK in the last 3 months.
Highest
Current $305.23
$455.00 (+49.07%)
Average
$388.25 (+27.20%)
Lowest
$315.00 (+3.20%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Matthew Taylor
Jefferies
Buy
Maintained
$455.00
+49.1%
06/18/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$380.00
+24.5%
06/12/2026
Joanne Wuensch
Citi
Buy
Reiterated
$385.00
+26.1%
05/28/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$330.00
+8.1%
05/04/2026
David Roman
Goldman Sachs
Hold
Maintained
$361.00
+18.3%
05/01/2026
Steven Lichtman
William Blair
Buy
Reiterated
-
-
05/01/2026
Jeff Johnson
Robert W. Baird
Buy
Maintained
$385.00
+26.1%
05/01/2026
Mathew Blackman
TD Cowen
Hold
Maintained
$355.00
+16.3%
05/01/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$355.00
+16.3%
05/01/2026
Robbie Marcus
J.P. Morgan
Buy
Reiterated
$400.00
+31%
05/01/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$420.00
+37.6%
05/01/2026
Pito Chickering
Deutsche Bank
Hold
Maintained
$315.00
+3.2%
05/01/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$418.00
+36.9%
05/01/2026
Lee Hambright
Bernstein
Buy
Maintained
$410.00
+34.3%
05/01/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$400.00
+31%
05/01/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$379.00
+24.2%
05/01/2026
Michael Matson
Needham
Buy
Reiterated
$418.00
+36.9%
05/01/2026
Matt Miksic
Barclays
Buy
Maintained
$394.00
+29.1%
05/01/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$360.00
+17.9%
05/01/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$435.00
+42.5%
05/01/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
$435.00
+42.5%
04/24/2026
Mike Kratky
Leerink Partners
Buy
Initiated
$410.00
+34.3%
04/13/2026
Nico Chen
DBS
Buy
Maintained
$450.00
+47.4%
03/18/2026
Danielle Antalffy
UBS
Hold
Reiterated
$380.00
+24.5%
03/17/2026
Unknown Analyst
Jefferies
Buy
Maintained
$465.00
+52.3%
03/05/2026
Patrick Wood
Morgan Stanley
Buy
Maintained
$445.00
+45.8%
02/02/2026
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.60 / $2.98
-12.86%miss
Revenue / Est. (USD)
6.02B / 6.33B
-4.89%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.02B
6.06B
7.17B
6.02B
Cost of goods sold
2.11B
2.12B
2.49B
2.19B
Cost of revenue
2.11B
2.12B
2.49B
2.19B
Research and development expenses
403.00M
409.00M
388.00M
409.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.00B
1.99B
2.15B
2.16B
Operating expense
2.59B
2.58B
2.72B
2.75B
Total operating expenses
4.70B
4.71B
5.22B
4.95B
Operating income
1.32B
1.35B
1.95B
1.07B
Other non operating income
-138.00M
-138.00M
541.00M
19.00M
EBT including unusual items
1.02B
1.03B
1.70B
850.00M
EBT excluding unusual items
1.24B
1.25B
1.81B
987.00M
Income tax expense
132.00M
170.00M
856.00M
105.00M
Effective tax rate
12.99%
16.52%
50.21%
12.35%
Other operating expenses
-
-
-
-
Net income
884.00M
859.00M
849.00M
745.00M
Net profit margin
14.68%
14.18%
11.84%
12.38%
Earnings per share
3.13
3.19
4.47
2.60
Interest and investment income
24.00M
28.00M
-
34.00M
Interest expense
-
-
-697.00M
-148.00M
Net interest expenses
24.00M
28.00M
-697.00M
-114.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.62B
1.66B
2.27B
1.37B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer